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Background: Nipah virus (NiV) is a highly pathogenic zoonotic agent in the family Paramyxoviridae that is
maintained in nature by bats. Outbreaks have occurred in Malaysia, Singapore, India, and Bangladesh and have
been associated with 40 to 75% case fatality rates. There are currently no vaccines or postexposure treatments
licensed for combating human NiV infection.
Methods and results: Four groups of ferrets received a single vaccination with different recombinant vesicular
stomatitis virus vectors expressing: Group 1, control with no glycoprotein; Group 2, the NiV fusion protein (F); Group
3, the NiV attachment protein (G); and Group 4, a combination of the NiV F and G proteins. Animals were
challenged intranasally with NiV 28 days after vaccination. Control ferrets in Group 1 showed characteristic clinical
signs of NiV disease including respiratory distress, neurological disorders, viral load in blood and tissues, and gross
lesions and antigen in target tissues; all animals in this group succumbed to infection by day 8. Importantly, all
specifically vaccinated ferrets in Groups 2-4 showed no evidence of clinical illness and survived challenged. All
animals in these groups developed anti-NiV F and/or G IgG and neutralizing antibody titers. While NiV RNA was
detected in blood at day 6 post challenge in animals from Groups 2-4, the levels were orders of magnitude lower
than animals from control Group 1.
Conclusions: These data show protective efficacy against NiV in a relevant model of human infection. Further
development of this technology has the potential to yield effective single injection vaccines for NiV infection.
Keywords: Nipah virus, Henipavirus, Vaccine, Vesicular stomatitis virus, Ferret, Fusion protein, Attachment protein,
Glycoprotein, Single-injection, ImmunityBackground
Nipah virus (NiV) and Hendra virus (HeV) represent the
highly pathogenic zoonotic agents in the paramyxovirus
genus Henipavirus with human case fatality rates ran-
ging between 40 and 75% [1]. These viruses are catego-
rized as biosafety level 4 (BSL4) pathogens due to the
significant morbidity and mortality associated with dis-
ease and the lack of approved vaccines and therapeutics* Correspondence: twgeisbe@utmb.edu
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stated.for human use. The primary reservoir for henipaviruses
are bats of the genus Pteropus [2]; however; the viruses
can be transmitted to many mammalian species including
humans. Currently, there are two distinct strains of NiV:
1) the Malaysia strain (NiVM) discovered in 1999 during
an outbreak on pig farms which resulted in spread to
humans [3]; and 2) the Bangladesh strain (NiVB), which
was discovered in India and Bangladesh during 2001 [4].
NiVB has been linked to direct transmission from bats to
humans and evidence suggests human to human trans-
mission is possible [5].
The near annual outbreaks of NiVB with high case fa-
tality rates [6] underscores the urgent need for effective
vaccines and therapeutics. To date, there have been fourd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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paviruses evaluated in animal models. Vaccinia and canar-
ypox viruses encoding the NiVM glycoproteins have
shown protection against NiVM in hamsters and pigs [7,8].
A recombinant adeno-associated vaccine expressing the
NiVM G protein completely protected hamsters against
homologous NiVM challenge and protected 50% of ani-
mals against heterologous HeV infection [9]. In addition, a
recombinant subunit vaccine based on the HeV G protein
(sGHeV) completely protects small animals against lethal
HeV and NiVM infection [10-13] and more recently was
shown to be efficacious in the robust African green mon-
key model of NiVM infection [14]. Though very promising,
the sGHeV vaccine requires a prime-boost strategy to con-
fer protection whereas a single-injection vaccine would be
particularly beneficial during outbreaks where there is
little time to employ lengthy vaccination regimens.
Single-injection recombinant vesicular stomatitis virus
(rVSV) vectors have been developed as vaccine candidates
against many important human pathogens such as papillo-
mavirus [15,16], human immunodeficiency virus (HIV)
[17-19], influenza virus [20], measles virus [21,22], respira-
tory syncytial virus [23,24], severe acute respiratory syn-
drome coronavirus [25], chikungunya virus [26], and
hemorrhagic fever viruses such as Lassa, Ebola, and
Marburg [27]. Single-cycle replication rVSVs have been
developed against NiV and have shown strong immuno-
genicity in mice vaccinated with rVSVs expressing either
the NiVM fusion protein (F) or the NiVM attachment pro-
tein (G) as high neutralizing antibody titers were gener-
ated [28]. These vaccine vectors were just recently shown
to provide homologous protection in the hamster model
of NiVM infection [29].
Here, we developed alternative rVSV vaccine vectors ex-
pressing either the NiVB F or NiVB G proteins. These vac-
cines were evaluated 28 days after a single dose vaccination
in the NiVM ferret model, which along with the African
green monkey, most faithfully recapitulates human disease
[30-32]. Each group of specifically vaccinated ferrets were
protected from NiVM-induced disease while the non-
specifically vaccinated ferrets succumbed to NiVM infec-
tion. To date, this is the first study to protect ferrets from
NiV infection using a single-injection vaccine.
Results
Recovery of rVSVΔG-NiVB/glycoprotein vectors
To investigate the protective efficacy of rVSV NiVB vac-
cine vectors against heterologous NiVM challenge in fer-
rets, we first developed and recovered two rVSVΔG
constructs expressing the NiVB F protein rVSV-ΔG-NiVB/
F-GFP (Figure 1A, blue) or NiVB G protein rVSV-ΔG-
NiVB/G-GFP (Figure 1A, yellow) using reverse genetics.
Propagation of these vectors requires VSV glycoprotein
(GInd) complementation (GInd*) of viruses where GInd isprovided in trans during infection [33]. GInd* complemen-
tation allows for single-cycle replication of vectors and re-
sults in expression of the NiVB glycoproteins and the
production non-infectious virions containing either glyco-
protein. As seen previously with similar NiVM rVSV vec-
tors [28], co-infection with GInd* rVSV-ΔG-NiVB/F-GFP
and GInd* rVSV-ΔG-NiVB/G-GFP produced infectious vi-
rions (rVSV-ΔG-NiVB/F/G-GFP) containing either gen-
ome with the NiVB F and NiVB G proteins incorporated in
the virion envelope (Figure 1A, Group 4 green-spiked vir-
ion) as evidenced by the ability of these virus preparations
to infect Vero cells (Figure 1B, *) and the inability of the
rVSV-ΔG-NiVB/F-GFP and rVSV-ΔG-NiVB/G-GFP to in-
fect cells without GInd* complementation (negative data
not shown). The rVSV-ΔG-NiVB/F/G-GFP virus stocks
were able to reach titers of up to 3 × 108 PFU/ml and in-
fection of Vero cells with these stocks resulted in syncytia
formation (Figure 1B). While this vaccine preparation
could undergo a single round of replication, it could not
be passaged further without GInd* complementation as
was observed with the rVSV-ΔG-NiVB/F-GFP and rVSV-
ΔG-NiVB/G-GFP vaccine preparations.Immunization of ferrets and examination of the humoral
immune response
Four groups of ferrets (Figure 1A) received a single vac-
cination of rVSV vectors as follows: Group 1 served as the
nonspecific vaccine control group and received GInd*
rVSV-ΔG-GFP; Group 2 received GInd* rVSV-NiVB/
F-GFP; Group 3 received GInd* rVSV-NiVB /G-GFP; and
Group 4 received the rVSV-ΔG-NiVB/F/G-GFP (Figure 2A,
triangles). Serum collected from each animal on the day of
vaccination (day -28) and just before challenge (day 0) was
analyzed for circulating IgG to the NiV F and NiV G pro-
teins by microsphere assay [30]. As expected, we did
not detect NiV F-specific Ig in sera before vaccination
(Figure 2B, day -28). We were able to detect Ig directed
at NiV F in sera of the Group 2 and 4 vaccinated co-
horts 28 days after vaccination but not in the ferrets
from Groups 1 and 3 (Figure 2B, day 0). Similar to the
analysis of NiV F-specific circulating IgG in vaccinated
ferrets, we were unable to detect IgG directed to NiV G
before vaccination (Figure 2C, day -28) and were able to
detect anti-NiV G IgG 28 days post vaccination (Figure 2C,
day -28). Animals in Group 3 had higher levels of circulat-
ing anti-NiV G IgG when compared to Group 4 and
surprisingly we were able to detect anti-NiV G IgG in
Group 2 animals although not to the levels of the NiVB
G-specifically vaccinated Group 3 animals (Figure 2C,
day -0). These results suggested that the animals in
Groups 2-4 and not Group 1 had generated a humoral
immune response to the rVSV-ΔG-NiVB antigens
delivered in a single injection.
Figure 1 Schematic rVSV NiVB vaccine genomes and groups. (A) Group 1: rVSV-ΔG-GFP expressing no glycoprotein; produces ‘bald’ virions,
Group 2 GInd*rVSV-NiVB /F-GFP expressing the NiVB F protein (blue); produces virions with F on the surface, Group 3 GInd*rVSV-NiVB /G-GFP
expressing the NiVB G protein (yellow); produces virions with G on the surface, Group 4 made from co-infection in Vero cells resulting in a
combination of rVSV-NiVB /F-GFP and rVSV-NiVB /G-GFP virions expressing the NiVB F and G proteins in the same cells; produces single-cycle
infectious virions with NiVB F and G proteins on the cell surface (green). (B) Phase and fluorescence microscopy of Vero cells infected with virions
from Group 4 displaying multinucleated syncytia cells * and cells positive for GFP expression.
Mire et al. Virology Journal 2013, 10:353 Page 3 of 13
http://www.virologyj.com/content/10/1/353NiV challenge of vaccinated ferrets
To determine whether vaccination with the rVSV-ΔG-
NiVB vectors could prevent NiVM disease course in ferrets,
we challenged ferrets intranasally with a lethal challenge
dose of NiVM on day 0 (Figure 2A, *). The animals were
closely monitored over the course of 22 days post challenge
(p.c.) for clinical signs of illness. The specifically vaccinated
animals in Groups 2-4 did not lose weight over the course
of the study (Figure 3A) and were 100% protected against
NiVM (Figure 3B), while the animals in the non-specifically
vaccinated Group 1 succumbed to infection on days 7 or 8
(Figure 2A, ^), respectively (Figure 3B, Table 1). Clinical
scores were recorded each day after challenge for each ani-
mal using a scoring system based on coat grooming, social
behavior, and provoked behavior. The clinical scores foreach animal correlated with the survival data as seen with
the mean clinical score for each animal in the vaccinated
groups having no score on any day p.c. versus the animals
in Group 1 having clinical scores on days 5 to 8 p.c. Clinical
signs in response to NiVB infection were more dramatic for
the animals in Groups 1 when compared to the animals in
the other three groups (Table 1). In all animals that
succumbed to NiVM infection, the gross pathologic findings
included varying severity of dehydration, ventral cervical
subcutaneous hemorrhage with edema (Figure 4A) and
crusting serous nasal discharge (Figure 4B). The internal
gross pathologic findings from animals in Group 1 in-
cluded varying severity of heavy, wet, diffusely mottled with
dark pin point foci throughout the pulmonary parenchyma,
multifocal pin point raised foci throughout the renal
Figure 2 NiV vaccine study design and circulating IgG post vaccination. (A) Flow chart showing the days of vaccination (triangles), days of
sampling (arrows), day of challenge (*),terminal succumbing to infection (^, day 7 or 8), and day of necropsy (^, day 22). Black triangle, Group 1;
blue triangle Group 2; yellow triangle Group 3; green triangle Group 4 vaccination. (B and C) Detection of specific anti-NiV F (B) and anti-NiV G
(C) IgG antibodies circulating in vaccinated ferrets. Mean fluorescence intensities (Mean FI) are shown on the y-axis and represent binding of
specific IgG. Error bars represent the s.d. of fluorescence intensity across 100 beads for each sample.
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megaly, and diffuse reticulation of the liver. Each animal
had diffuse hemorrhagic interstitial pneumonia (Figure 4C)
and splenomegaly with multifocal necrosis (pic 4D, *).
Additionally, diffuse reticulation of the liver (Figure 4D, +)
and multifocal renal hemorrhage (Figure 4D, arrow) were
noted. There were no external or internal gross pathologic
findings of note in any of the Group 2-4 animals at the
study endpoint (Figure 2A, day 22 ^).
Histopathological and immunohistochemical analysis of
NiVM-infected ferrets
Tissues examined from animals in Groups 2-4 had no sig-
nificant histologic findings (Figure 5A,E,I, and M) and were
devoid of NiV antigen (Figure 5B,F,J, and N). In contrast,
tissues examined from ferrets in control Group 1 had
substantial histologic findings which included mild to
moderate interstitial pneumonia with marked congestion,
endothelial syncytial cell formation, and respiratory epithe-
lial syncytial cell formation (Figure 5C, arrow head). Severe
lymphoid depletion, necrosis, hemorrhage, fibrin deposition
and syncytial cell formation were observed throughout
the spleen (Figure 5G). Glomerular tufts in the kidney
had multifocal segmental to global fibrin deposition and
endothelial syncytial cell formation (Figure 5K). Ferretsin control Group 1 also had detectable NiV antigen sys-
temically, with the endothelium, scattered mononuclear
cells, and syncytial cells (endothelial and epithelial) of the
lung (Figure 5D), spleen (Figure 5H), kidney (Figure 5L),
and brain (Figure 5P) having strong immunolabeling for
NiV antigen.
NiV load
To determine if there was NiVM replication in animals p.c.,
viremia was assessed by virus isolation from serum (nega-
tive data not shown) and by qRT-PCR on whole blood
samples (Figure 6A). NiVM genome equivalents (GEq)
were detected in all blood samples from day 6 p.c. While
we detected NiVM GEq for all animals on day 6, the Group
1 animals had over 100 fold more detectable GEq and an
increase in GEq from terminal bleeds on day 7 or 8
(Figure 6A). However, none of the specifically vacci-
nated animals had any detectable NiVM RNA in ter-
minal blood samples on day 21 (Figure 6A). NiVM
RNA was also detected systemically in the tissues of all
animals that succumbed to infection in control Group
1 and in the spleen of one animal from Group 4 on the
study end date (Figure 6B), though no NiVM antigen
was detected by immunohistochemistry (data not
shown), whereas NiVM RNA was not detected in the
Figure 3 Protection from NiVM mediated disease. (A) Weight
curves of vaccinated ferrets are shown and represent the average
percent weight of animals post NiVM challenge in comparison to
day 0. Error bars represent the s.d. (B) Kapplan-Meier survival curve
for each vaccine group post NiVM challenge.
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itionally, we were able to isolate NiVM from all tissues
sampled in all animals from control Group 1, with the
exception of the liver for animal 1-3 (Figure 6C). Over-
all, the level of detection of NiVM RNA in tissues and
blood correlated with outcome gross pathology, and
histology (Figure 4, Figure 5, and Table 1) for each animal.
Neutralizing NiVM antibody titers pre and post challenge
with NiVM
To further address the antibody response to rVSV-ΔG-
NiVB vaccination and after NiVM challenge, we character-
ized the circulating antibodies before and after vaccination
for their neutralizing activity using a plaque reduction
neutralization titer (PRNT50) assay. All four groups lacked
neutralizing antibody titers before vaccination (Figure 7A).
On the day of challenge, animals from control Group 1
did not have neutralizing antibody titers against NiVM
whereas all ferrets from Groups 2-4 had neutralizing anti-
bodies against NiVM (Figure 7B), although it appeared that
Groups 2 and 3 had higher titers than Group 4. Neutraliz-
ing antibody titers were also assessed for all animals fromterminal bleeds on the day of death (day 7 or 8) or at day
21. All animals that succumbed to NiVM challenge in
Group 1 had consistently lower neutralizing antibody ti-
ters against NiVM when compared to the neutralizing
antibodies found in animals from Groups 2-4 (Figure 7C).
Discussion
While significant progress on a veterinary vaccine for one
henipavirus, HeV, has been made [34], the development of
effective human vaccines and antiviral drugs for high con-
sequence pathogens such as NiV is a much slower and
complicated process. In particular, the restriction of infec-
tious NiV work to BSL-4 containment has hampered pro-
gress. Conventional clinical trials with viruses such as NiV
are not practical. To address the development of counter-
measures for exotic pathogens such as NiV the FDA im-
plemented the Animal Efficacy Rule in 2002. This rule
specifically applies to the development of countermeasures
when human efficacy studies are not possible or ethical.
Briefly, this rule permits the evaluation of vaccines or ther-
apeutics using data generated from studies performed in
animal models that faithfully recapitulate human disease.
There are currently at least eight animal models for NiV
including the IFNAR-KO mouse model [35]; the guinea
pig model [36]; the pig model [8,37-39]; the cat model
[10,11]; the golden Syrian hamster model [7,40-42]; the
ferret model [30,43]; and two nonhuman primate models,
one in squirrel monkeys [44] and the other in African
green monkeys [32]. While each of these models shares at
least one or more aspects seen in human pathogenesis
and can contribute to vaccine and therapeutic testing, the
two animal models which completely emulate the patho-
genesis seen in human cases to date are the ferret model
and the African green monkey model. These models re-
capitulate what is seen during human infection with severe
respiratory and neurologic disease and a generalized
vasculitis.
Based on this knowledge, the ferret model was chosen
for the initial evaluation of our rVSV-ΔG-NiVB-F/G-GFP
vectors. This model should be considered as the initial
small animal screening model for vaccines against NiV, es-
pecially since the recombinant sGHeV protein vaccine has
been shown to be efficacious in ferrets [12] and African
green monkeys [14]. While sGHeV vaccine has proven to
have utility against NiV infection in these two animal
models, the vaccine regimen requires two doses using a
prime-boost strategy with the two adjuvants CpG oligo-
deoxynucleotide (ODN) 2006 and Alhydrogel included in
the vaccine formulation [14]. Here, we evaluated rVSV-
ΔG-NiVB-F/G-GFP vectors as single-injection vaccines
against lethal NiVM challenge in ferrets.
Non-specifically vaccinated control animals in Group 1
did not produce anti-NiV F or anti-NiV G IgGs, did not
produce significant neutralizing antibody titers against





Clinical and gross pathology
1-1 Fever (d5-7); Depression (d6-7); lethargy (d6-7); loss of appetite
(d6-7); labored breathing (d6-7). Animal euthanized on d7.
++/6,
++/7
Thrombocytopenia (d7); Lymphopenia (d6-7); >3-fold
increase in BUN (d7); rash on ventral surface of neck; lungs
with severe congestion and hemorrhage of all lobes;
enlarged spleen; darkened liver, edema of left kidney capsule.
1-2 Fever (d5); depression (d6-8); lethargy (d6-8) loss of appetite
(d6-8); labored breathing (d6-8); dehydration (d8), ocular and nasal
discharge (d7-8); Hind limb paresis (d8) Animal euthanized on d8.
++/6,
++/8
Thrombocytopenia (d8); Lymphopenia (d6,8); >3-fold increase
in BUN (d8); hypoalbuminemia (d6,8); ecchymotic rash on
ventral surface of neck; lungs with severe congestion and
hemorrhage of all lobes; enlarged spleen; darkened liver.
1-3 Fever (d4-7); depression (d5-7); lethargy (d5-7); loss of appetite
(d5-7); labored breathing (d6-7); ocular and nasal discharge
(d6-7); Hind limb paresis (d7). Animal euthanized d7.
++/6,
++/7
Thrombocytopenia (d6-7); Lymphopenia (d6-7);
hypoalbuminemia (d6-7); ecchymotic rash on ventral
surface of neck; lungs with severe congestion and
hemorrhage of all lobes; enlarged spleen; darkened liver.
1-4 Fever (d5-7); Depression (d6-8); lethargy (d7-8); loss of
appetite (d6-8); labored breathing (d6-8); hind limb
tremors (d8). Animal euthanized on d8.
++/6,
++/8
Thrombocytopenia (d8); Lymphopenia (d6,8);
hypoalbuminemia (d8); lungs with severe congestion and
hemorrhage of all lobes; enlarged spleen; darkened liver.
1-5 Fever (d5-7); Depression (d6-7); lethargy (d7); loss of appetite
(d5-7); dehydration (d7); labored breathing (d6-7).
Animal euthanized on d7.
++/6,
++/7
Thrombocytopenia (d7); Lymphopenia (d6-7);
hypoalbuminemia (d7); lungs with severe congestion and
hemorrhage of all lobes; enlarged spleen; darkened liver.
2-1 None None
2-2 None +/6 None
2-3 None None
2-4 None None
2-5 Mild fever (d7) +/6 None
3-1 None None
3-2 None None
3-3 None +/6 None
3-4 None None
3-5 None +/6 None
4-1 None None
4-2 None None
4-3 None +/6 None
4-4 None +/6 None
4-5 None None
aAnimals euthanized due to complications from NiV-induced disease.
bqRT-PCR positive blood/day p.c.: +, ≤ 5 log10 NiVM GEq/ml of blood; ++, ≥ 5 log10 NiVM GEq /ml of blood.
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disease as they displayed clinical symptoms and pathology
consistent with NiVM infection, and had viral RNA and
infectious virus isolated systemically. Animals in Group 2
vaccinated with GInd* rVSV-ΔG-NiVB/F-GFP generated
anti-NiV F IgGs (and possible cross-reactive NiV G IgG,
Figure 2C) and neutralizing antibody titers against NiVM
and were protected from NiVM-induced disease with one
animal (Table 1, 2-5) having a low-grade fever on day 7 p.c.
Similarly, ferrets in Group 3 vaccinated with GInd* rVSV-
ΔG-NiVB/G-GFP generated anti-NiV G IgGs and neu-
tralizing antibody titers against NiVM and were protected
from NiVM-induced disease. Using vectors that were inde-
pendent of GInd* complementation, ferrets in Group 4 vac-
cinated with rVSV-ΔG-NiVB-F/G-GFP generated anti-NiVF and anti-NiV G IgGs and neutralizing antibody titers
against NiVM and were also protected from NiVM-induced
disease. The observation that the percent weight growth
was less than Group 2 and 3 (Figure 3A) could have been
due to the social housing of these animals where it is pos-
sible that certain members of the cohort were out com-
peted for extra food as some animals in this group reached
percent weight growth of animals from the other groups.
While the protection afforded to Groups 2-4 did not ap-
pear to be sterile as virus replication could be detected by
the presence of viral RNA in whole blood at day 6 p.c., it
was only detected in two animals per group versus all ani-
mals in Group 1 (Table 1) and the mean virus replication
was 100 times lower than what was detected in animals
from Group 1 (Figure 6A).
Figure 4 Gross pathology of ferrets succumbing to NiVM mediated disease. Representative gross pathology from animals in Group 1
challenged with NiVM. (A) Ventral cervical subcutaneous hemorrhage with edema. (B) Crusting serous nasal discharge. (C) Diffuse hemorrhagic
interstitial pneumonia. (D) Splenomegaly with multifocal necrosis (*), diffuse reticulation of the liver (+), and multifocal renal hemorrhage (white arrow).
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in the rVSV-ΔG-NiVB/G-GFP vaccinated ferrets was in-
teresting considering our experience with the Bioplex
assay and sGHeV vaccinated ferrets and African green
monkeys where we have never detected cross-reactivity
against NiVM F from G vaccinated animals. One pos-
sible explanation is that the antibodies produced inresponse to the NiVB G results in the formation of some
antibodies that can recognize NiVM F since the target
antigen in the Bioplex assay is NiVM F. Our experience
with the sGHeV vaccine may not be applicable here as
this cross-reactivity may be a single-cycle replicating
vaccine observation. While not within the scope of this
study, the further examination of the avidity of these
Figure 5 H&E and immunohistochemistry of ferret tissues. Representative H&E stained tissues (A, C, E, G, I, K, M, and O) and immuno-
histochemistry of tissues labeled with a NiV N protein-specific polyclonal rabbit antibody (B, D, F, H, J, L, N, and P). Tissues from representative
vaccinated ferrets from groups 2-4; lung (A, B), spleen (E, F), kidney (I, J), and brain, choroid plexus (M, N). Tissues from representative control
Group 1 ferrets; lung (C, D), spleen (G, H), kidney (K, L), and brain, choroid plexus (O, P). C, (arrow head) Respiratory epilthelial syncytia; D, (arrow)
NiV antigen-positive respiratory epithelial syncytia, G, (white asterisk) lymphoid depletion in spleen; K, (*) fibrin deposition in glomerular tuft of
kidney. Images taken: lung 40x, spleen 20x, kidney 40x, brain 40x.
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NiV vaccine platform is developed.
As it is difficult to determine which vaccine platform
would be best for the human population against deadly
pathogens such as NiV, it is important to develop and test
a number of platforms to combat a potential outbreak. A
preventive vaccine would be important for several popula-
tions: 1) the general population during NiV outbreaks par-
ticularly in endemic areas in India and Bangladesh; 2)
healthcare workers and family members involved in pa-
tient care and management in endemic regions; 3)
personnel involved in outbreak response missions; 4) la-
boratory workers conducting research on NiV; and 5)
military and other service personnel susceptible to the use
of NiV as a biological weapon. While multi-dose vaccine
regimens would be feasible for laboratory and healthcare
workers and some military personnel in stable settingswith defined risk, an outbreak setting or a case of deliber-
ate release would require rapidly conferred protection
with a single administration. Here we describe the protec-
tion of ferrets from NiVM-induced disease using single-
injection rVSV vaccine vectors expressing the NiVB F and/
or NiVB G proteins. To date, this is the first study to show
efficacy of a vaccine against NiV using a single administra-
tion in the ferret model. Based on the success of this
study, these vectors should be evaluated further in the Af-
rican green monkey model against NiVB challenge as this
strain appears to be the most pathogenic in humans [6].
Methods
Plasmid design and construction
RNA was isolated from NiVB virus stocks (NiVB #200401066
was obtained from a patient from the 2004 outbreak in
Bangladesh (kindly provided by Dr. Thomas Ksiazek)
Figure 6 Viral load in NiVM challenged ferrets. Viral load in ferrets as detected by genome equivalents (GEq) by qRT-PCR from (A) blood as
GEq/ml and (B) from tissues a GEq/g (Animal 4-1 was negative for NiVM antigen in spleen). Right upper (R.U.), right middle (R.M.), right lower
(R.L.), left upper (L.U.), left middle (L.M.), left lower (L.L.), lymph node (LN). (C) PFU/g of NiVM isolated from tissues of ferrets in Group 1. Liver (L),
spleen (S), kidney (K), adrenal gland (A). Error bars represent the s.d.
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the Galveston National Laboratory (GNL) at the Uni-
versity of Texas Medical Branch (UTMB). The RNA
was used to make cDNA with gene specific primers and
the genes were amplified using gene specific primers
(NiVB F or G) containing MluI and NheI restriction
sites at the 5′ and 3′ ends respectively. The PCR ampli-
fied products and pΔG-VSV-2.6 plasmid were restric-
tion digested with MluI and NheI and gel purified.
Purified products and vector were ligated and positive
colonies were screened and sequenced for positive
constructs.rVSV vaccine vectors and challenge virus
The rVSV NiVB vaccines (rVSV-ΔG-NiVB/F-GFP and
rVSV-ΔG-NiVB/G-GFP) and rVSV-ΔG-GFP were recov-
ered using methods previously described [33]. The
rVSVΔG viruses were propagated on BHK-21 cells trans-
fected with 2 μg of pCAGGS-GInd expressing the VSV
glycoprotein (GInd) and titered as previously described
[33]. Viruses complemented with VSV GInd are denoted as
GInd* rVSV-ΔG-GFP, G*rVSV-ΔG-NiVB/F-GFP, and G*
rVSV-ΔG-NiVB/G-GFP. To make the vaccine in Group 4
(Figure 1A), Vero cells were co-infected with G*rVSV-ΔG-
NiVB/F-GFP and G* rVSV-ΔG-NiVB/G-GFP at MOI 5 for
Figure 7 Reciprocal NiVM serum neutralizing antibody titers.
Neutralizing antibody titers which reduce virus infectivity are shown
for all groups on the (A) day of vaccination showing a lack of
neutralizing antibody for all groups, (B) on the day of challenge
showing neutralizing antibodies for all groups except Group 1, and
(C) on the terminal bleed days showing high levels of neutralizing
antibodies for Groups 2-4 and low neutralizing antibodies for Group
1. Error bars represent the s.d.
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on BHK-21 cells complemented with VSV GInd.
NiVM #1999011924 was obtained from a patient from
the 1999 outbreak in Malaysia (kindly provided by Dr.
Thomas Ksiazek). NiVM was chosen for challenge in fer-
rets based on our lethality data with this particular stock
at the time of the study. The virus was propagated onVero E6 cells in Eagle’s minimal essential medium
(EMEM) supplemented with 10% fetal calf serum. The
NiVM challenge virus stock was assessed for the pres-
ence of endotoxin using The Endosafe®-Portable Test
System (PTS) (Charles River, Wilmington, MA). Virus
preparations were diluted 1:10 in Limulus Amebocyte
Lysate (LAL) Reagent Water (LRW) per manufacturer’s
directions and endotoxin levels were tested in LAL
Endosafe®-PTS cartridges as directed by the manufac-
turer. Each preparation was found to be below detect-
able limits while positive controls showed that the tests
were valid.
Statistics
Conducting animal studies in BSL-4 severely restricts the
number of animal subjects, the volume of biological sam-
ples that can be obtained and the ability to repeat assays
independently and thus limit statistical analysis. Conse-
quently, data are presented as the mean calculated from
replicate samples, not replicate assays, and error bars rep-
resent the standard deviation across replicates.
Animals
Animal studies were performed in BSL-4 biocontainment
at the GNL at the UTMB at Galveston and were approved
by the UTMB Institutional Animal Care and Use Commit-
tee (IACUC). Animal research was conducted in compli-
ance with the Animal Welfare Act and other Federal
statutes and regulations relating to animals and experi-
ments involving animals and adheres to the principles
stated in the eighth edition of the Guide for the Care and
Use of Laboratory Animals, National Research Council,
2013. The facility where this research was conducted is
fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International.
Twenty female ferrets weighing 0.75-1 kg were housed in
groups of 3 and 2 animals per vaccine group. Before vac-
cination, subjects were anesthetized by i.m. injection with
ketamine-acepromazine-xylazine (KAX) cocktail and had
transponder chips (BioMedic Data Systems, Seaford, DE)
implanted subcutaneously for animal identification and
temperature monitoring. For procedures, animals were
anesthetized with KAX and vaccinated with ~ 1 × 107 PFU
by i.m. injection on day -28 (Figure 2A). Animals were in-
oculated intranasally (i.n.) with ~ 5 × 103 pfu of NiVM in
1 ml of Dulbecco’s minimal essential medium (DMEM)
(Sigma-Aldrich, St Louis, MO) 28 days after vaccination
(Figure 2A, *). Animals were anesthetized for clinical
examination including temperature, respiration quality,
blood collection, and on days 0, 6, and 21 p.c. Before
and after challenge animals were assessed daily for
weight, temperature, and scored on a scale of 0 of 9 for
clinical observations based on coat appearance, social
behavior, and provoked behavior; animals scoring 7 or
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the vaccine cohorts were euthanized at the study endpoint
on day 22 p.c. whereas the subjects in Group 1 had to be
euthanized according to approved humane end points on
day 7 or 8 p.c. All other subjects survived until the end of
the study.
Measurement of serum or plasma NiV F and G
specific antibodies
Ferret serum collected at indicated time points was tested
for IgG antibodies against NiV F and G using previously de-
veloped multiplexed microsphere assays [30]. 96-well filter
plates were primed with PBS. Test sera were diluted in PBS
at 1:10 for pre vaccination time points and 1:10,000 for
time points after vaccination. Biotinylated goat anti-ferret
IgG and streptavidin-phycoerythrin (strep-PE) were also di-
luted in PBS. Coupled microspheres (sG-HeV, sG-NiV, sF-
Hev, sF-NiV) were prepared by sonication for 1 minute
followed by vortex mixing for 1 minute each and then di-
luted in PBS. Priming liquid was removed from plates using
a Bio-Plex Pro II Wash Station (Bio-Rad, Hercules, CA)
and 100 μL containing 1500 of each coupled microsphere
was added to each well. The microsphere mixture was re-
moved by vacuum, 100 μL of diluted test sera was added to
appropriate wells and incubated at room temperature (RT)
for 30 minutes while shaking in the dark. Diluted test sam-
ples were removed by vacuum and 100 μL of diluted bio-
tinylated goat anti-ferret (1:500) (Pierce, ThermoScientific,
Rockford, IL) was added to each well and incubated as pre-
viously described above. Liquid was removed by vacuum
and 100 μL of strep-PE (1:1000) (Qiagen, Valencia, CA) was
added to each well and again incubated for 30 minutes. All
liquid was removed from plates with a vacuum manifold
and washed twice with 300 μL PBS, removing liquid
between wash steps. Finally, 125 μL of PBS was added to
each well and incubated for 2 minutes as described above.
Samples were assayed for mean fluorescence intensity
(MFI) across at least a 100 bead region performed on
the BioPlex-200 machine and analyzed using Bio-Plex
Manager Software (v 6.1) (Bio-Rad). MFI and the stand-
ard deviation (s.d.) of fluorescence intensity across 100
beads were determined for each sample and plotted.
NiVM serum neutralization assays
PRNTs were determined using a conventional serum
neutralization assay. Briefly, sera were serially diluted two-
fold, and incubated with ~ 100 pfu of NiV for 1 hour at
37°C. Virus and antibodies were then added to individual
wells of 6-well plates of confluent Vero cell monolayers.
Plates were stained with neutral red 2 days after infection
and plaques were counted 24 hours after staining. The
50% neutralization titer (PRNT50) was determined as the
serum dilution at which there was a 50% reduction in
plaque counts versus control wells.Specimen collection and processing in NiV-infected ferrets
Blood was collected and placed in MiniCollect EDTA
tubes or serum tubes (Greiner Bio One, Monroe, NC). Im-
mediately following sampling, 100 μl of blood was added
to 600 μl of AVL viral lysis buffer (Qiagen) for RNA ex-
traction. For tissues, approximately 100 mg was stored in
1 ml RNAlater (Qiagen) for 7 days to stabilize RNA. RNA-
later was completely removed, and tissues were homoge-
nized in 600 μl RLT buffer (Qiagen) in a 2-ml cryovial
using a tissue lyser (Qiagen) and stainless steel beads. The
tissues sampled included right lung upper lobe, right lung
middle lobe, right lung lower lobe, left lung upper lobe,
left lung middle lobe, left lung lower lobe, liver, spleen,
kidney, adrenal gland, pancreas, and brain (frontal cortex).
All blood samples were inactivated in AVL viral lysis buf-
fer, and tissue samples were homogenized and inactivated
in RLT buffer prior to removal from the BSL-4 laboratory.
Subsequently, RNA was isolated from blood and swabs
using the QIAamp viral RNA kit (Qiagen) and from tis-
sues using the RNeasy minikit (Qiagen) according to the
manufacturer’s instructions supplied with each kit.
Hematology and serum biochemistry
Prior to the study, baseline blood and sera were collected
via the anterior vena cava from all 20 ferrets. On days -28,
0, 6, and 21 blood was collected from all animals. Complete
blood counts of total white blood cell counts, white blood
cell differentials, red blood cell counts, platelet counts,
hematocrit values, total hemoglobin concentrations, mean
cell volumes, mean corpuscular volumes, and mean cor-
puscular hemoglobin concentrations were analyzed from
blood collected in MiniCollect EDTA tubes (Greiner Bio
One) using a Hemavet HV950FS instrument per manufac-
turer’s instructions (Drew Scientific, Oxford, CT). Serum
analysis of blood chemistries was performed using a VetS-
can classic analyzer and comprehensive diagnostic profile
rotors measuring of albumin (ALB), amylase, alanine ami-
notransferase (ALT), alkaline phosphatase (ALP), calcium,
glucose, total protein, total bilirubin (TBIL), blood urea ni-
trogen (BUN), creatinine (CRE), phosphorus, sodium, and
total protein (Abaxis, Union City, CA). All blood and
serum samples were processed and analyzed immediately
after collection.
Histopathology and immunohistochemistry
Necropsy was performed on all subjects. Tissue samples
of all major organs were collected for histopathologic and
immunohistochemical examination and were immersion-
fixed in 10% neutral buffered formalin for at least 21 days
in BSL-4. Subsequently, formalin was changed; specimens
were removed from BSL-4, processed in BSL-2 by conven-
tional methods and embedded in paraffin and sectioned at
5 μm thickness. For immunohistochemistry, specific anti-
NiV immunoreactivity was detected using an anti-NiV N
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Christopher Broder) at a 1:5000 dilution for 30 minutes.
The tissue sections were processed for immunohisto-
chemistry using the Dako Autostainer (Dako, Carpinteria,
CA). Secondary antibody used was biotinylated goat anti-
rabbit IgG (Vector Laboratories, Burlingame, CA) at 1:200
for 30 minutes followed by Dako LSAB2 streptavidin-HRP
(Dako) for 15 minutes. Slides were developed with Dako
DAB chromagen (Dako) for 5 minutes and counterstained
with hematoxylin for one minute. Non-immune rabbit
IgG was used as a negative staining control.
Detection of NiV load
RNA was isolated from blood or tissues and analyzed
using primers/probe targeting the N gene and intergenic
region between N and P of NiV for quantitative real-time
PCR (qRT-PCR) with the probe used here being 6-
carboxyfluorescein (6FAM)-5′ CGT CAC ACA TCA
GCT CTG ACG A 3′-6 carboxytetramethylrhodamine
(TAMRA) (Life Technologies, Carlsbad, CA). NiV RNA
was detected using the CFX96 detection system (Bio-Rad)
in One-step probe qRT-PCR kits (Qiagen) with the follow-
ing cycle conditions: 50°C for 10 minutes, 95°C for
10 seconds, and 40 cycles of 95°C for 10 seconds and 59°C
for 30 seconds. Threshold cycle (CT) values representing
NiV genomes were analyzed with CFX Manager Software,
and data are shown as genome equivalents (GEq). To
create the GEq standard, RNA from NiV challenge stocks
was extracted and the number of NiV genomes was cal-
culated using Avogadro’s number and the molecular
weight of the NiV genome. Virus titration was performed
by plaque assay with Vero cells from all serum and control
tissue samples. Briefly, increasing 10-fold dilutions of the
samples were adsorbed to Vero cell monolayers in dupli-
cate wells (200 μl); the limit of detection was 25 pfu/ml.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CEM designed the vaccines and vaccination study, carried out the animal
vaccination and infection studies, processed animal tissues and blood,
analyzed data, and drafted the manuscript. KMV cloned, recovered,
characterized, and propagated the vaccines, processed animal tissues and
blood, and participated in manuscript preparation. RWC carried out animal
vaccination and infection studies, processed animal tissues and blood,
analyzed data, and participated in manuscript preparation. KNA participated
in animal infection studies, processed animal tissues and blood, performed
serology, performed virus isolation, performed qRT-PCR, analyzed data, and
participated in manuscript preparation. KAF participated in animal infection
studies, provided veterinary pathology expertise, analyzed data, and
participated in manuscript preparation. MAW participated in design of
vaccine construction and study design, analyzed data, and edited
manuscript. TWG conceived the study, supported the work with research funds
from the National Institutes of Health (U01 AI082121) and UTMB, analyzed data,
and edited the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank Joan B. Geisbert and Daniel J. Deer for study support, Jessica
Graber for expert technical assistance with the ABSL-2 and ABSL-4 samplecollection during the vaccination and infection studies, and the staff of the
UTMB Animal Resources Center for animal care. Opinions, interpretations,
conclusions, and recommendations are those of the authors and are not
necessarily endorsed by UTMB.
Author details
1Galveston National Laboratory, University of Texas Medical Branch, 301
University Blvd., Galveston, TX, USA. 2Department of Microbiology and
Immunology, University of Texas Medical Branch, 301 University Blvd.,
Galveston, TX, USA. 3Department of Microbiology, Immunology, and
Biochemistry, University of Tennessee Health Science Center, 858 Madison
Ave., Memphis, TN, USA.
Received: 21 November 2013 Accepted: 3 December 2013
Published: 13 December 2013
References
1. Wang L, Harcourt BH, Yu M, Tamin A, Rota PA, Bellini WJ, Eaton BT:
Molecular biology of Hendra and Nipah viruses. Microbes Infect 2001,
3:279–287.
2. Halpin K, Hyatt AD, Fogarty R, Middleton D, Bingham J, Epstein JH, Abdul
Rahman S, Hughes T, Smith C, Field HE: Pteropid bats are confirmed as
the reservoir hosts of henipaviruses: a comprehensive experimental
study of virus transmission. Am J Trop Med Hyg 2011, 85:946.
3. Chua KB, Goh KJ, Wong KT, Kamarulzaman A, Tan PS, Ksiazek TG, Zaki SR,
Paul G, Lam SK, Tan CT: Fatal encephalitis due to Nipah virus among pig-
farmers in Malaysia. Lancet 1999, 354:1257–1259.
4. Chadha MS, Comer JA, Lowe L, Rota PA, Rollin PE, Bellini WJ, Ksiazek TG,
Mishra A: Nipah virus-associated encephalitis outbreak, Siliguri, India.
Emerg Infect Dis 2006, 12:235–240.
5. Gurley ES, Montgomery JM, Hossain MJ, Bell M, Azad AK, Islam MR, Molla MA,
Carroll DS, Ksiazek TG, Rota PA, et al: Person-to-person transmission of Nipah
virus in a Bangladeshi community. Emerg Infect Dis 2007, 13:1031–1037.
6. Luby SP, Gurley ES: Epidemiology of henipavirus disease in humans.
Curr Top Microbiol Immunol 2012, 359:25–40.
7. Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A,
Marianneau P, Chua KB, Lam SK, Buckland R, Deubel V, Wild TF: Nipah virus:
vaccination and passive protection studies in a hamster model. J Virol
2004, 78:834–840.
8. Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, Roth JA,
Czub M: Recombinant nipah virus vaccines protect pigs against
challenge. J Virol 2006, 80:7929–7938.
9. Ploquin A, Szecsi J, Mathieu C, Guillaume V, Barateau V, Ong KC, Wong KT,
Cosset FL, Horvat B, Salvetti A: Protection against henipavirus infection by
use of recombinant adeno-associated virus-vector vaccines. J Infect Dis
2013, 207:469–478.
10. McEachern JA, Bingham J, Crameri G, Green DJ, Hancock TJ, Middleton D,
Feng YR, Broder CC, Wang LF, Bossart KN: A recombinant subunit vaccine
formulation protects against lethal Nipah virus challenge in cats.
Vaccine 2008, 26:3842–3852.
11. Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, Russell G, Green D,
McEachern J, Pritchard LI, Eaton BT, et al: Feline model of acute nipah virus
infection and protection with a soluble glycoprotein-based subunit vaccine.
J Virol 2006, 80:12293–12302.
12. Pallister JA, Klein R, Arkinstall R, Haining J, Long F, White JR, Payne J, Feng YR,
Wang LF, Broder CC, Middleton D: Vaccination of ferrets with a recombinant
G glycoprotein subunit vaccine provides protection against Nipah virus
disease for over 12 months. Virol J 2013, 10:237.
13. Pallister J, Middleton D, Wang LF, Klein R, Haining J, Robinson R, Yamada M,
White J, Payne J, Feng YR, et al: A recombinant Hendra virus G
glycoprotein-based subunit vaccine protects ferrets from lethal Hendra
virus challenge. Vaccine 2011, 29:5623–5630.
14. Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, LaCasse R, Geisbert JB,
Feng YR, Chan YP, Hickey AC: A Hendra virus G glycoprotein subunit
vaccine protects African green monkeys from Nipah virus challenge.
Sci Transl Med 2012, 4:146ra107.
15. Reuter JD, Vivas-Gonzalez BE, Gomez D, Wilson JH, Brandsma JL, Greenstone HL,
Rose JK, Roberts A: Intranasal vaccination with a recombinant vesicular stoma-
titis virus expressing cottontail rabbit papillomavirus L1 protein provides
complete protection against papillomavirus-induced disease. J Virol 2002,
76:8900–8909.
Mire et al. Virology Journal 2013, 10:353 Page 13 of 13
http://www.virologyj.com/content/10/1/35316. Roberts A, Reuter JD, Wilson JH, Baldwin S, Rose JK: Complete protection
from papillomavirus challenge after a single vaccination with a vesicular
stomatitis virus vector expressing high levels of L1 protein. J Virol 2004,
78:3196–3199.
17. Egan MA, Chong SY, Rose NF, Megati S, Lopez KJ, Schadeck EB, Johnson JE,
Masood A, Piacente P, Druilhet RE, et al: Immunogenicity of attenuated
vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag
proteins: comparison of intranasal and intramuscular vaccination routes.
AIDS Res Hum Retroviruses 2004, 20:989–1004.
18. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori D,
Roberts A, Buonocore L, Rose JK: An effective AIDS vaccine based on live
attenuated vesicular stomatitis virus recombinants. Cell 2001, 106:539–549.
19. Rose NF, Roberts A, Buonocore L, Rose JK: Glycoprotein exchange vectors
based on vesicular stomatitis virus allow effective boosting and
generation of neutralizing antibodies to a primary isolate of human
immunodeficiency virus type 1. J Virol 2000, 74:10903–10910.
20. Roberts A, Buonocore L, Price R, Forman J, Rose JK: Attenuated vesicular
stomatitis viruses as vaccine vectors. J Virol 1999, 73:3723–3732.
21. Schlereth B, Buonocore L, Tietz A, Meulen Vt V, Rose JK, Niewiesk S:
Successful mucosal immunization of cotton rats in the presence of
measles virus-specific antibodies depends on degree of attenuation of
vaccine vector and virus dose. J Gen Virol 2003, 84:2145–2151.
22. Schlereth B, Rose JK, Buonocore L, ter Meulen V, Niewiesk S: Successful vaccine-
induced seroconversion by single-dose immunization in the presence of
measles virus-specific maternal antibodies. J Virol 2000, 74:4652–4657.
23. Johnson JE, McNeil LK, Megati S, Witko SE, Roopchand VS, Obregon JH,
Illenberger DM, Kotash CS, Nowak RM, Braunstein E, et al: Non-propagating,
recombinant vesicular stomatitis virus vectors encoding respiratory
syncytial virus proteins generate potent humoral and cellular immunity
against RSV and are protective in mice. Immunol Lett 2013, 150:134–144.
24. Kahn JS, Roberts A, Weibel C, Buonocore L, Rose JK: Replication-competent
or attenuated, nonpropagating vesicular stomatitis viruses expressing
respiratory syncytial virus (RSV) antigens protect mice against RSV
challenge. J Virol 2001, 75:11079–11087.
25. Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, Roberts A: Long-
term protection from SARS coronavirus infection conferred by a single
immunization with an attenuated VSV-based vaccine. Virology 2005,
340:174–182.
26. Chattopadhyay A, Wang E, Seymour R, Weaver SC, Rose JK: A chimeric vesiculo/
alphavirus is an effective alphavirus vaccine. J Virol 2013, 87:395–402.
27. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R, Volchkov V,
Klenk HD, Feldmann H, Stroher U: Properties of replication-competent vesicu-
lar stomatitis virus vectors expressing glycoproteins of filoviruses and arena-
viruses. J Virol 2004, 78:5458–5465.
28. Chattopadhyay A, Rose JK: Complementing defective viruses that express
separate paramyxovirus glycoproteins provide a new vaccine vector
approach. J Virol 2011, 85:2004–2011.
29. Lo MK, Bird BH, Chattopadhyay A, Drew CP, Martin BE, Coleman JD, Rose JK,
Nichol ST, Spiropoulou CF: Single-dose replication-defective VSV-based
Nipah virus vaccines provide protection from lethal challenge in Syrian
hamsters. Antiviral Res 2013, 101C:26-29. doi: 10.1016/j.antiviral.2013.10.012.
30. Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, McEachern
JA, Green D, Hancock TJ, Chan YP, et al: A neutralizing human monoclonal
antibody protects against lethal disease in a new ferret model of acute
nipah virus infection. PLoS Pathog 2009, 5:e1000642.
31. Clayton BA, Middleton D, Bergfeld J, Haining J, Arkinstall R, Wang L, Marsh
GA: Transmission routes for Nipah virus from Malaysia and Bangladesh.
Emerg Infect Dis 2012, 18(12):1983-93. doi: 10.3201/eid1812.120875.
32. Geisbert TW, Daddario-DiCaprio KM, Hickey AC, Smith MA, Chan YP, Wang LF,
Mattapallil JJ, Geisbert JB, Bossart KN, Broder CC: Development of an acute
and highly pathogenic nonhuman primate model of Nipah virus infection.
PLoS One 2010, 5:e10690.
33. Whitt MA: Generation of VSV pseudotypes using recombinant DeltaG-
VSV for studies on virus entry, identification of entry inhibitors, and
immune responses to vaccines. J Virol Methods 2010, 169:365–374.
34. Mendez D, Buttner P, Speare R: Response of Australian veterinarians to
the announcement of a Hendra virus vaccine becoming available.
Aust Vet J 2013, 91:328–331.
35. Dhondt KP, Mathieu C, Chalons M, Reynaud JM, Vallve A, Raoul H, Horvat B:
Type I interferon signaling protects mice from lethal henipavirus
infection. J Infect Dis 2013, 207:142–151.36. Middleton DJ, Morrissy CJ, van der Heide BM, Russell GM, Braun MA,
Westbury HA, Halpin K, Daniels PW: Experimental Nipah virus infection in
pteropid bats (Pteropus poliocephalus). J Comp Pathol 2007, 136:266–272.
37. Berhane Y, Weingartl HM, Lopez J, Neufeld J, Czub S, Embury-Hyatt C, Goolia
M, Copps J, Czub M: Bacterial infections in pigs experimentally infected
with Nipah virus. Transbound Emerg Dis 2008, 55:165–174.
38. Middleton DJ, Westbury HA, Morrissy CJ, van der Heide BM, Russell GM,
Braun MA, Hyatt AD: Experimental Nipah virus infection in pigs and cats.
J Comp Pathol 2002, 126:124–136.
39. Weingartl H, Czub S, Copps J, Berhane Y, Middleton D, Marszal P, Gren J,
Smith G, Ganske S, Manning L, Czub M: Invasion of the central nervous
system in a porcine host by Nipah virus. J Virol 2005, 79:7528–7534.
40. Georges-Courbot MC, Contamin H, Faure C, Loth P, Baize S, Leyssen P,
Neyts J, Deubel V: Poly(I)-poly(C12U) but not ribavirin prevents death in a
hamster model of Nipah virus infection. Antimicrob Agents Chemother
2006, 50:1768–1772.
41. Guillaume V, Contamin H, Loth P, Grosjean I, Courbot MC, Deubel V,
Buckland R, Wild TF: Antibody prophylaxis and therapy against Nipah
virus infection in hamsters. J Virol 2006, 80:1972–1978.
42. Rockx B, Brining D, Kramer J, Callison J, Ebihara H, Mansfield K, Feldmann H:
Clinical outcome of henipavirus infection in hamsters is determined by
the route and dose of infection. J Virol 2011, 85:7658–7671.
43. Pallister J, Middleton D, Crameri G, Yamada M, Klein R, Hancock TJ, Foord A,
Shiell B, Michalski W, Broder CC: Chloroquine administration does not
prevent Nipah virus infection and disease in ferrets. J Virol 2009,
83:11979–11982.
44. Marianneau P, Guillaume V, Wong T, Badmanathan M, Looi RY, Murri S, Loth
P, Tordo N, Wild F, Horvat B, Contamin H: Experimental infection of
squirrel monkeys with Nipah virus. Emerg Infect Dis 2010, 16:507–510.
doi:10.1186/1743-422X-10-353
Cite this article as: Mire et al.: Single injection recombinant vesicular
stomatitis virus vaccines protect ferrets against lethal Nipah virus
disease. Virology Journal 2013 10:353.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
